Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses.

Mehta, Darshan; Davis, Matthew; Epstein, Andrew J; Wensel, Brian; Grinnell, Todd; Williams, G Rhys

Mehta, Darshan; Davis, Matthew; Epstein, Andrew J; Wensel, Brian; Grinnell, Todd; Williams, G Rhys.

Afiliación

Mehta D; Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, 01752, USA. Darshan.Mehta@sunovion.com.
Davis M; Medicus Economics, LLC, Milton, MA, USA.
Epstein AJ; Medicus Economics, LLC, Milton, MA, USA.
Wensel B; Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, 01752, USA.
Grinnell T; Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, 01752, USA.
Williams GR; Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, 01752, USA.

Neurol Ther ; 9(2): 585-598, 2020 Dec.

Article en En | MEDLINE | ID: mdl-32949379

Palabras clave

Anti-seizure drug; Early initiation; Economic benefit; Epilepsy; Eslicarbazepine acetate; Focal seizures; Healthcare resource utilization

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Neurol Ther Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google